Pfizer Stock Price, News & Analysis

Pfizer Inc. (NYSE: PFE) announced the initiation of the TALAPRO-3 trial, a global Phase 3 study investigating the efficacy and safety of talazoparib combined with enzalutamide in men with DNA damage response (DDR)-deficient metastatic castration-sensitive prostate cancer. The trial will enroll approximately 550 participants across 285 sites in 28 countries, with a primary endpoint of radiographic progression-free survival (rPFS). The first patient was dosed in Glendale, California, and results are anticipated in late 2024.

ViiV Healthcare and Halozyme Therapeutics have entered a global collaboration that grants ViiV exclusive access to Halozyme's ENHANZE® drug delivery technology for HIV treatments. ViiV will pay $40 million upfront, with potential milestone payments totaling up to $175 million per target. This partnership aims to enhance the development of long-acting HIV therapies, reducing the frequency of medication. The PH20 enzyme allows for efficient large-volume subcutaneous injections, potentially addressing treatment challenges for patients and improving their experience.

ViiV Healthcare and Halozyme Therapeutics have formed a collaboration to utilize Halozyme's ENHANZE® drug delivery technology for HIV treatment and prevention. ViiV will pay Halozyme $40 million upfront, with potential future payments totaling $175 million based on development milestones. This partnership aims to develop ultra-long acting HIV medicines, reducing the treatment burden for patients. Halozyme's enzyme technology enables rapid delivery of large volumes of medication, potentially extending dosing intervals beyond current standards. The collaboration could lead to innovative options in HIV therapies.

Pfizer and the Academic Research Organization from Hospital Israelita Albert Einstein announced positive results from the STOP-COVID study published in the New England Journal of Medicine. The study evaluated tofacitinib in 289 hospitalized COVID-19 pneumonia patients not on ventilation. Results showed a lower cumulative incidence of death or respiratory failure at 28 days for tofacitinib (18.1%) versus placebo (29.0%). Although promising, tofacitinib is not yet authorized for COVID-19 treatment and should not be used in patients with active serious infections.

Pfizer (NYSE: PFE) will hold a conference call on July 28, 2021, at 10 a.m. EDT to discuss its Second Quarter 2021 Performance Report. Investors can access the live webcast and report details on the company's investor site. Registration for the call is recommended in advance. A transcript and replay will be available within 24 hours for 90 days. Participants can also join by calling (833) 711-4984 in the US or (916) 900-3769 internationally, using the password 'Second Quarter Earnings'.

Pfizer (PFE) and BioNTech (BNTX) announced a plan to provide 500 million COVID-19 vaccine doses to the U.S. government at a not-for-profit price, aimed at supporting global vaccination efforts. This includes 200 million doses by the end of 2021 and 300 million in early 2022. The U.S. government will donate these doses to low- and lower-middle-income countries through COVAX. Pfizer and BioNTech aim to produce up to 3 billion doses in 2021, enhancing their supply chain capabilities. Deliveries will begin in August 2021.

Pfizer Inc. (NYSE:PFE) announced that the U.S. FDA has approved PREVNAR 20™, a 20-valent Pneumococcal Conjugate Vaccine, for preventing invasive disease and pneumonia caused by pneumococcal serotypes in adults ages 18 and older. This vaccine includes additional serotypes linked to high fatality rates and antibiotic resistance. Following this approval, the CDC's ACIP will meet to discuss vaccination recommendations. With this launch, Pfizer aims to enhance protection against significant pneumococcal diseases, addressing more serotypes than previous vaccines, which could lead to a notable market impact.

Pfizer Inc. (NYSE: PFE) announced the enrollment of the first participants in a new study examining the coadministration of its 20-valent pneumococcal conjugate vaccine (20vPnC) alongside a booster dose of the Pfizer-BioNTech COVID-19 Vaccine. This trial, involving 600 adults aged 65 and older, aims to assess safety and immune responses over a six-month follow-up. Participants will be randomized into three groups: one receiving both vaccines, one receiving 20vPnC plus a placebo, and another receiving the COVID-19 vaccine booster plus placebo.

Pfizer and BioNTech have entered a new agreement with the European Commission to supply 900 million doses of the COVID-19 vaccine COMIRNATY® to the EU, with an optional additional 900 million doses. This follows a prior commitment of 600 million doses for 2021. Deliveries are set to start in December 2021 and continue into 2023, potentially totaling 2.4 billion doses. Both companies emphasize the importance of ongoing vaccinations due to the continued spread of COVID-19 and are committed to adapting their vaccine for emerging variants.